

Vigmed receives CE mark approval for their SWiNG product

For further
information contact:

CEO
Finn Ketler
+46 42 600 5311 or

Director of Quality
Assurance &
Regulatory Affairs
Ola Lindau
+46 42 600 5315

Vigmed announced today that they have received the CE mark for commercial sales of their new product Vigmed® SWiNG.

The SWiNG products add to Vigmed's range of unique and patented safety devices developed by the company in their continuous efforts to eliminate the risks and hazards of needlestick injuries.

SWiNG is the first safety cover for hypodermic needles that once activated automatically prevents needlestick injuries, both during and after injection.

“This is a major milestone for both our company and for medical staff around the world. The launch of this product comes at a timely moment with the focus on current Ebola-crisis in mind”, says Vigmed CEO Finn Ketler. “We strive to make the workplace of medical staff a safer place, and offering this safety device to the market will further contribute to this effort, as well as adding safety to one of the most common medical procedures in the world.”

The CE-mark enables Vigmed to immediately increase their presence in the market.

“Our distributors can now start introducing this line to their markets and we are confident the products will be positively received by both our customers and end users”, says Vigmed Sales Director Europe, Mike Dooley.

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden, and has approximately 20 employees. Vigmed's share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 400 shareholders. Remium Nordic AB is the Company's Certified Advisor. Additional information such as company description, a video presentation and risk factors can be found on Vigmed's home page: www.vigmed.com/investor